<DOC>
	<DOCNO>NCT00785317</DOCNO>
	<brief_summary>The purpose study evaluate effect breast postmenopausal woman randomize either oestradiol combination DRSP E2 combination NETA six month .</brief_summary>
	<brief_title>Effects Estradiol Menopausal Breast</brief_title>
	<detailed_description />
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Naturally postmenopausal , symptomatic , apparently healthy woman , need hormone therapy age 50 70 year BMI &gt; 18 ≤30 kg/m2 without previous history breast disease recruit study . They amenorrheic least 12 month le 12 month S FSH value &gt; 40 IU/L . They free sex hormone treatment least three month inclusion . General contraindication HT accord Swedish product label . Age &gt; 60 year . BMI ≤18 ≥30 kg/m2 . Any previous history cancer . Any previous history breast disease abnormal mammogram . In addition : hypertension ( systolic BP &gt; 160 mm Hg diastolic &gt; 100 mm Hg ) , hyperlipidemia ( total cholesterol &gt; 8.0 mmol/L triglyceride &gt; 3.0 mmol/L ) , diabetes mellitus , history thromboembolic disease , heart failure , liver disease porphyria , undiagnosed vaginal bleeding . No sex hormone treatment least three month inclusion . No concomitant treatment know influence hormone metabolism ( warfarin , rifampicin , carbamazepine , griseofulvin , hydantoin , primidone , barbiturate , broad spectrum antibiotic ) accept .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Postmenopausal Hormone Replacement Therapy</keyword>
</DOC>